tradingkey.logo
tradingkey.logo
Suchen

Castle Biosciences Inc

CSTL
Zur Watchlist hinzufügen
24.110USD
-0.600-2.43%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
731.26MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Castle Biosciences Inc Unternehmen

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

Castle Biosciences Inc Informationen

BörsenkürzelCSTL
Name des UnternehmensCastle Biosciences Inc
IPO-datumJul 25, 2019
CEOMaetzold (Derek J)
Anzahl der mitarbeiter761
WertpapierartOrdinary Share
GeschäftsjahresendeJul 25
Addresse505 S Friendswood Drive
StadtFRIENDSWOOD
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl77546
Telefon18667889007
Websitehttps://castlebiosciences.com/
BörsenkürzelCSTL
IPO-datumJul 25, 2019
CEOMaetzold (Derek J)

Führungskräfte von Castle Biosciences Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
127.71K
-6.72%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
98.03K
+11.43%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
35.63K
+38.36%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
33.00K
+41.42%
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Frank Stokes
Mr. Frank Stokes
Chief Financial Officer
Chief Financial Officer
--
--
Mr. G. Bradley Cole
Mr. G. Bradley Cole
Independent Director
Independent Director
--
--
Ms. Kimberlee S. Caple
Ms. Kimberlee S. Caple
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Derek J. Maetzold
Mr. Derek J. Maetzold
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
279.21K
--
Ms. Kristen M. Oelschlager
Ms. Kristen M. Oelschlager
Chief Operating Officer
Chief Operating Officer
127.71K
-6.72%
Mr. Tobin W. (Toby) Juvenal
Mr. Tobin W. (Toby) Juvenal
Chief Commercial Officer
Chief Commercial Officer
98.03K
+11.43%
Ms. Ellen Goldberg
Ms. Ellen Goldberg
Independent Director
Independent Director
40.92K
+33.40%
Mr. Miles D. Harrison
Mr. Miles D. Harrison
Independent Director
Independent Director
35.63K
+38.36%
Mr. Rodney Cotton
Mr. Rodney Cotton
Independent Director
Independent Director
33.00K
+41.42%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Castle Biosciences Inc?

Die fünf größten Anteilseigner von Castle Biosciences Inc sind: Mr. Derek J. Maetzold

Wie viele Institutionen halten Anteile an Castle Biosciences Inc (CSTL)?

Mit Stand vom 2026Q1 halten 413 Institutionen Anteile an Castle Biosciences Inc, mit einem Gesamtmarktwert von etwa 27.62M, was 91.06% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1802863.00 gestiegen.